Drug Database
Back to search

France· FR:68009899

EVRYSDI 0,75 mg/mL, poudre pour solution buvable

A risdiplam product containing risdiplam, registered in France by ROCHE REGISTRATION (ALLEMAGNE), on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC M09AX10

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedEVRYSDI 0,75 mg/mL, poudre pour solut…ATCM09AX10REGISTER NO.FR:68009899PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about risdiplamAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Risdiplam is registered in 14 of 19 countries.

Countries holding a registration under ATC M09AX10 (risdiplam), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose
Search risdiplam products by name

Risdiplam · ATC M09AX10

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of risdiplam costs, country by country.

Normalised to the WHO defined daily dose (5 mg), the median price runs from $20.14 in France to $872.62 in Switzerland — a ×43 gap.

  • France: $20.14 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Risdiplam · price per daily dose (5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$872.62
  • FR France$20.14
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
RISDIPLAM
Manufacturer
ROCHE REGISTRATION (ALLEMAGNE)
Country
France (FR)
ATC code
M09AX10
ATC class
Risdiplam
Defined daily dose
5 mg, O
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930229385
    1 flacon(s) en verre jaune(brun) + 1 adaptateur pour flacon + 2 seringues orales ambrées graduées réutilisables de 1 mL + 2 seringue orales ambrées graduées réutilisables de 6 mL + 1 seringue orale ambrée graduée réutilisable de 12 mL
    EUR 7.66

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for risdiplam.

Graded by severity as the source publishes them — 2 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check risdiplam against other medicinesHow interaction checks work

Risdiplam · interactions on record

2 records

  • 2 moderate

Most severe, free to view

  • Methylnaltrexone bromideA06AH01moderate
  • MetforminA10BA02moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Risdiplam in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All risdiplam products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Evrysdi
  • Liechtenstein · Evrysdi
  • Norway · Evrysdi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f19c2f54-47ac-43d5-a169-9080807d9394
GET /v1/drugs/f19c2f54-47ac-43d5-a169-9080807d9394?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "68009899",
  "date_amm": "2021-03-26",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/21/1531",
  "substance": "RISDIPLAM",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "poudre pour solution buvable",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about risdiplam.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console